Deals: Page 79
-
Meet the healthcare and pharma industry vet who will be Teva's next chairman
On January 1, 2015, Teva board member Yitzhak Peterburg will become Chairman of the board as Phillip Frost, who has been called controversial, steps down.
By Nicole Gray • Dec. 2, 2014 -
Mylan strikes deal to make Gilead's HIV drugs more accessible to poor nations
Gilead and Mylan are staying true to the theme for this year's World AIDS Day: "Focus, Partner, Achieve: An AIDS-Free Generation."
By Nicole Gray • Dec. 2, 2014 -
Done deal: Pfizer completes acquistion of Baxter's vaccines
The most valuable additions are vaccines that protect against meningitis and tick-borne encephalitis.
By Nicole Gray • Dec. 2, 2014 -
Job cuts ahead: GSK plans US workforce restructuring
After a rough year, Glaxo plans on saving money (partially) by trimming the fat.
By Nicole Gray • Dec. 1, 2014 -
Top UK fund manager to launch major new biotech fund in 2015
The man who is often considered the best fund manager in Britain, Neil Woodford, is planning to launch a fund full of biotech stocks—including many that are unlisted.
By Nicole Gray • Nov. 25, 2014 -
In search of new opportunities, Bayer considers selling $2.5B diabetes unit
Germany-based Bayer is working with Credit Suisse to sell its $2.5 billion diabetes arm while gearing up to invest in more lucrative life-sciences businesses.
By Nicole Gray • Nov. 25, 2014 -
BioMarin makes $840M gamble, buys Prosensa and its orphan drugs
Prosensa has been developing orphan drug candidates to treat Duchenne muscular dystrophy, a rare disease that leads to severe muscle degeneration and often kills by age 30.
By Sy Mukherjee • Nov. 24, 2014 -
Another first: Gilead spends $125M on priority review voucher for mystery drug
The Neglected Tropical Disease Priority Review Voucher has not been a paragon of success in drug development, but Gilead has a candidate in the pipeline—and everyone wants to know what it is.
By Nicole Gray • Nov. 20, 2014 -
These execs are on Sanofi's CEO short list
Sanofi is quietly compiling a list of candidates to replace sacked CEO Chris Veibacher. And executives from Takeda, Smith & Nephew, Bayer, and Novartis are reportedly on the short list.
By Nicole Gray • Nov. 20, 2014 -
Novartis aims to put more 'tech' in biotech
Under the guidance of CEO Joe Jimenez, Novartis is taking bio-feedback to a new level in its quest to develop companion remote-monitoring devices for its therapies. Step 1? A deal with Google.
By Nicole Gray • Nov. 20, 2014 -
FDA
Has the price of developing drugs really doubled in the last 11 years?
A Tufts study finds that the cost of drug development has doubled to $2.56 billion over the last 11 years. But some groups remain highly skeptical.
By Nicole Gray • Nov. 19, 2014 -
Docs breathe sigh of relief as Actavis buyout ends Valeant-Allergan drama
"Finally, no more drama—and thank goodness Valeant didn't acquire Allergan!" That, in a nutshell, is how a group of surveyed ophthalmologists feels about Actavis' $66 billion acquisition of the Botox-maker.
By Nicole Gray • Nov. 18, 2014 -
Deep Dive
2 DRG analysts dish on the 'unprecedented' Valeant-Allergan struggle
Drs. Anne-Elise Tobin and Sangha Mitra, Decision Resource Group analysts, shared their thoughts on the M&A story of the year (or maybe decade) with BioPharma Dive.
By Nicole Gray • Nov. 17, 2014 -
UPDATED: Actavis buys Allergan for $66 billion
The Wall Street Journal reports that the Actavis and Allergan boards are meeting this week to talk a cash-and-stock takeover while Bill Ackman and Valeant are left out in the cold.
By Sy Mukherjee • Nov. 17, 2014 -
Apollo Global Manangement joins bidding wars for GSK's mature drugs
Reuter reports that Leon Black's private equity firm, Apollo, is joining the auction to bid on GSK's mature drugs—a portfolio worth roughly $3 billion.
By Nicole Gray • Nov. 14, 2014 -
Let's make a deal: Allergan, Actavis talk $60 billion merger
As it fends off Valeant's hostile advances, Allergan has entered productive talks with Actavis focusing on a $60 billion merger agreement. But they come with a deadline.
By Nicole Gray • Nov. 13, 2014 -
Gilead, AbbVie hep C drugs score 97% cure rates, Regulus gets cold shoulder
Regulus' new hep C injectable isn't getting much love at the popular Boston liver conference. But Gilead and AbbVie have reasons to smile.
By Nicole Gray • Nov. 12, 2014 -
Activist investor Bill Ackman's $2 billion fallback plan for Valeant
Ackman has taken a $2 billion stake in the Pfizer spinoff Zoetis Inc. And if his hostile bid for Allergan falls through, the animal health specialist could be his next acquisition conquest.
By Sy Mukherjee • Nov. 12, 2014 -
Shire CEO: The future looks bright—who needs AbbVie?
Flemming Ornskov isn't sweating the busted AbbVie deal. Instead, the firm plans to concentrate on acquisitions and rare diseases to achieve an ambitious $10 billion in annual sales by 2020.
By Nicole Gray • Nov. 12, 2014 -
FDA
GE Healthcare and Takeda to take on liver disease R&D together
GE Healthcare will provide the diagnostic imaging technology to support Takeda's research into common liver diseases.
By Nicole Gray • Nov. 12, 2014 -
Decisions, decisions: UCB to sell its generic unit to private equity firms
UCB is selling its U.S. generic division to Advent International and Avista Capital for $1.53 billion.
By Nicole Gray • Nov. 10, 2014 -
Isis Pharma wins $10M neurodegeneration treatment milestone from Biogen
The development deal between Biogen Idec and Isis Pharmaceuticals is bearing fruit as Isis begins clinical trials for its third drug for Biogen.
By Nicole Gray • Nov. 10, 2014 -
Political unrest in Russia nixes deal with German pharma company
Germany-based Fresenius has changed its mind about expanding its presence in Russia through a joint venture with Sistema JSFC thanks to ongoing tensions over Ukraine.
By Nicole Gray • Nov. 10, 2014 -
Salix Pharmaceuticals' inventory woes ruined potential Allergan buyout
A review of inventory revealed larger-than-communicated wholesaler supplies of Salix's top drug, Xifaxan (rifaximin), meaning sales will most likely be lower than anticipated.
By Nicole Gray • Nov. 10, 2014 -
This billionaire hedge fund manager may sue over busted AbbVie-Shire deal
Paul Singer is known to be litigious—and he isn't happy that the AbbVie-Shire merger fell through.
By Nicole Gray • Nov. 7, 2014
Previous
